World's First Solid-Tumor CAR-T Cell Therapy Product Approved in China
Quick Answer / What Happened
According to a June 22, 2026 report from The Paper, China's National Medical Products Administration approved 科济药业's Claudin18.2-targeted autologous humanized CAR-T cell therapy, 恺力美® / 舒瑞基奥仑赛注射液, for selected patients with advanced gastric or gastroesophageal junction adenocarcinoma. The reported indication is Claudin18.2-positive, HER2-negative disease after failure of at least two prior treatment lines. The report described the product as the world's first approved CAR-T cell therapy for solid tumors. For international patients, the significance is clear: China's cell and gene therapy field is no longer only following global development. In selected areas, it is helping define new treatment categories.
The Paper reported that on June 22, 2026, 恺力美® was officially approved by China's National Medical Products Administration. The product was independently developed by Shanghai-based CARsgen Therapeutics, a Chinese biopharmaceutical company focused on CAR-T cell therapy.
The article described the approval as a milestone for cell and gene therapy in China. It stated that the therapy is intended for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least second-line treatment failure.
Why This Matters
The source framed the approval as an important step from "following" and "running alongside" toward a more leading role in the frontier field of cell and gene therapy. In the context of solid tumor CAR-T development, that framing is notable. CAR-T therapy has already changed parts of blood-cancer care, but solid tumors have historically been much harder because of tumor microenvironment barriers, target selection, immune suppression, and tumor heterogeneity.
The article explained that malignant tumors are often divided into blood cancers and solid tumors. Solid tumors, including gastric cancer, lung cancer, liver cancer, and others, account for the majority of malignant tumors. The report emphasized that solid tumors are harder to treat with CAR-T approaches because they grow in organ tissues and are protected by complex tumor microenvironments.
Gastric cancer is also a major cancer burden in China. The report stated that China's annual new gastric cancer cases account for about 40% of the global total. For patients with advanced gastric or gastroesophageal junction adenocarcinoma after standard treatment failure, available treatment options can be limited.
Against that background, the approval of a Claudin18.2-targeted CAR-T product is clinically and symbolically important. It does not mean CAR-T is now suitable for all gastric cancer patients. It means China has approved a highly specific cellular therapy pathway for a biomarker-defined group of patients with advanced disease after prior treatment failure.
What International Patients Should Understand
According to the report, Professor Shen Lin of Peking University Cancer Hospital led large-scale multicenter clinical research together with more than twenty leading medical institutions across China.
The report also noted that confirmatory randomized controlled study results for 舒瑞基奥仑赛 were published in The Lancet. It presented this as evidence that the therapy's clinical value had received recognition in a leading international medical journal.
This matters for international patients because it shows that China's advanced treatment development is not only happening inside individual hospitals or isolated laboratories. In this case, the source describes a model involving a Chinese biopharmaceutical company, a major cancer hospital, multiple leading institutions, multicenter clinical research, and international publication.
The Paper's article also discussed research exploring whether CAR-T therapy may create more benefit when used earlier in the disease course or earlier in the treatment sequence, when a patient's immune function and organ function may be better.
The report cited a 2024 Nature Medicine investigator-initiated trial in which 舒瑞基奥仑赛 was used as sequential therapy after first-line treatment for gastric cancer. In four patients with target lesions, the report stated that the objective response rate reached 100%; two patients later underwent surgery after CAR-T infusion and achieved nearly five years of long-term survival in that selected small research cohort. These results, from a small investigator-initiated trial, should not be read as expected outcomes for individual patients or as a general prognosis for patients with this diagnosis.
The article also cited preliminary investigator-initiated pancreatic cancer adjuvant-therapy data presented at ESMO 2025. It reported that among six participants, five had significant CA19-9 decreases after infusion, and one patient who completed 52 weeks of follow-up had no disease recurrence at that time.
What This Does NOT Mean
These early-stage findings should not be read as standard treatment expectations. They are research signals from selected investigator-initiated studies. Their importance is that Chinese institutions are actively testing whether CAR-T therapy can move beyond late-line rescue treatment and into earlier, more strategic treatment windows.
This is exactly the kind of development this column is designed to track. The news is not simply that a drug was approved. It is that China approved a first-in-category cellular therapy for a difficult solid tumor setting, supported by domestic multicenter research and international publication.
For global patients and families, this helps reframe China as a serious advanced oncology destination. China may offer more than lower-cost care or shorter access pathways in selected cases. It may also offer access to advanced treatment ecosystems, biomarker-driven oncology, large cancer-center networks, and cell therapy development that patients outside China may not know how to evaluate.
How CareNavigator Can Help Patients Evaluate Relevance
CareNavigator helps patients and families understand whether a China-based specialist review or advanced therapy pathway may be worth exploring, based on diagnosis, biomarker status, prior treatment history, records, timing, hospital availability, and travel readiness. The goal is to help families compare more clearly, identify better access or timing when available, reduce avoidable delays in record preparation, intake coordination, and option comparison where possible, and compare cost structures to identify more cost-effective pathways where appropriate.
FAQ
What product was approved in China?
The Paper reported that China's NMPA approved 恺力美® / 舒瑞基奥仑赛注射液, a Claudin18.2-targeted autologous humanized CAR-T cell therapy developed by CARsgen Therapeutics.
Which patients is it reported to be for?
The reported indication is Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least second-line treatment failure. Patient-specific suitability depends on biomarker status, prior treatment history, clinical condition, and treating-team review.
Why is this news important?
The Paper reported it as the world's first approved CAR-T cell therapy product for solid tumors. Solid tumor CAR-T has been technically difficult, so approval in a biomarker-defined gastric/GEJ cancer setting is a significant China advanced-treatment milestone. Official NMPA and company source records provide additional product-detail context for families and clinicians reviewing this development.
Does this mean CAR-T is now an option for all solid tumor patients?
No. This is a specific therapy for a specific biomarker-defined indication reported in the source. Broader use in other cancers or earlier treatment settings remains dependent on clinical evidence, regulatory approval, hospital pathways, and physician review.
Tell us what your family is trying to decide. Contact CareNavigator and provide your diagnosis, current treatment situation, records, biomarker results, and key questions. We can help you search for relevant advanced treatment pathways in China, understand which options may be worth reviewing, and prepare for informed conversations with qualified medical teams.
Related CareNavigator Resources
- China Advanced Treatment Updates
- Why China
- How CareNavigator Helps
- China Treatment Navigation Guide
- CAR-T Cell Therapy in China
- CAR-T Treatment in China: Cost, Eligibility, and Pathway
- CAR-T Cell Therapy in China: A Patient Guide
Source-Led Update Note
This article summarizes publicly available reporting and cited source materials about medical developments in China. It is not CareNavigator's independent clinical assessment of the therapy and should not be read as medical advice for any individual patient. CareNavigator helps patients organize records, understand whether a reported China-based pathway may be relevant, and prepare for informed conversations with qualified medical teams. Patient eligibility, risks, benefits, availability, and treatment decisions should be assessed by licensed clinicians and the responsible medical institution.
Source Notes
Primary media source: The Paper / 澎湃新闻 article captured as PDF via Baijiahao, titled "全球首款实体瘤CAR-T细胞治疗产品在中国获批上市", published 2026-06-22, reporter Jiang Lelai.
Original Baijiahao URL shown in PDF: https://baijiahao.baidu.com/s?id=1868680571434471234&wfr=spider&for=pc
Official NMPA approval source: National Medical Products Administration page for 科济药业's Claudin18.2-targeted autologous humanized CAR-T therapy, 恺力美® / 舒瑞基奥仑赛注射液. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20260622143203120.html
Company announcement context: CARsgen / PRNewswire announcement describing satricabtagene autoleucel and the approval milestone. https://www.prnewswire.com/news-releases/carsgens-satri-cel-becomes-the-worlds-first-approved-car-t-cell-therapy-product-for-solid-tumors-302806312.html
Additional source to verify before final publication: The Lancet confirmatory randomized controlled study for 舒瑞基奥仑赛注射液, a Claudin18.2-targeted CAR-T therapy in advanced gastric or gastroesophageal junction cancer.